NXL vs. NTRB, PDEX, VANI, EDAP, GUTS, PSTV, LUNG, MDAI, DXR, and NEPH
Should you be buying Nexalin Technology stock or one of its competitors? The main competitors of Nexalin Technology include Nutriband (NTRB), Pro-Dex (PDEX), Vivani Medical (VANI), EDAP TMS (EDAP), Fractyl Health (GUTS), Plus Therapeutics (PSTV), Pulmonx (LUNG), Spectral AI (MDAI), Daxor (DXR), and Nephros (NEPH). These companies are all part of the "medical equipment" industry.
Nexalin Technology vs. Its Competitors
Nutriband (NASDAQ:NTRB) and Nexalin Technology (NASDAQ:NXL) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.
Nutriband has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Nexalin Technology has a beta of 3.59, indicating that its share price is 259% more volatile than the S&P 500.
Nexalin Technology has lower revenue, but higher earnings than Nutriband. Nutriband is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.
19.7% of Nutriband shares are owned by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are owned by institutional investors. 54.1% of Nutriband shares are owned by company insiders. Comparatively, 25.3% of Nexalin Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Nexalin Technology had 4 more articles in the media than Nutriband. MarketBeat recorded 4 mentions for Nexalin Technology and 0 mentions for Nutriband. Nexalin Technology's average media sentiment score of 0.27 beat Nutriband's score of 0.00 indicating that Nexalin Technology is being referred to more favorably in the news media.
Nutriband has a net margin of -398.29% compared to Nexalin Technology's net margin of -5,057.14%. Nutriband's return on equity of -85.40% beat Nexalin Technology's return on equity.
Nutriband presently has a consensus target price of $13.00, suggesting a potential upside of 73.80%. Nexalin Technology has a consensus target price of $5.00, suggesting a potential upside of 228.95%. Given Nexalin Technology's stronger consensus rating and higher possible upside, analysts plainly believe Nexalin Technology is more favorable than Nutriband.
Summary
Nexalin Technology beats Nutriband on 9 of the 15 factors compared between the two stocks.
Get Nexalin Technology News Delivered to You Automatically
Sign up to receive the latest news and ratings for NXL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nexalin Technology Competitors List
Related Companies and Tools
This page (NASDAQ:NXL) was last updated on 10/20/2025 by MarketBeat.com Staff
